Mersana Therapeutics Inc. and a subsidiary of Merck KGaA in Darmstadt, Germany, formed a research collaboration and commercial license agreement to discover novel Immunosynthen antibody-drug conjugates directed against up to two targets.
FDA granted traditional approval to Merck’s pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1).
